Replimune Group, Inc. (NASDAQ:REPL) Stock Has Consensus Target Price of $12.00

Shares of Replimune Group, Inc. (NASDAQ:REPL) have earned an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $12.00.

REPL has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Replimune Group in a research report on Monday, October 5th. Wolfe Research raised Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price target on the stock in a research note on Friday, August 7th. Weiss Ratings cut Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. Finally, Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $11.00 to $17.00 in a research report on Tuesday, August 4th.

Insider Transactions at Replimune Group

In related news, CAO Andrew Schwendenman sold 7,632 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $98,987.04. Following the completion of the transaction, the chief accounting officer directly owned 99,425 shares in the company, valued at $1,289,542.25. This trade represents a 7.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $510,252.77. Following the transaction, the chief executive officer owned 708,151 shares of the company’s stock, valued at $9,184,718.47. This trade represents a 5.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 79,124 shares of company stock worth $1,038,364 over the last quarter. 5.40% of the stock is owned by corporate insiders.

Institutional Trading of Replimune Group

A number of institutional investors and hedge funds have recently bought and sold shares of REPL. BlackRock Inc. acquired a new stake in shares of Replimune Group during the second quarter worth about $99,171,000. Montanova Capital LLC boosted its stake in shares of Replimune Group by 4.0% in the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock valued at $48,595,000 after purchasing an additional 168,000 shares during the period. Opaleye Management Inc. purchased a new position in shares of Replimune Group in the second quarter valued at approximately $15,332,000. Commodore Capital LP purchased a new position in shares of Replimune Group in the fourth quarter valued at approximately $13,851,000. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Replimune Group by 1.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company’s stock valued at $8,719,000 after purchasing an additional 20,742 shares in the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Replimune Group Stock Performance

Shares of REPL stock opened at $11.75 on Tuesday. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 1.00. The company has a 50-day moving average of $13.86 and a two-hundred day moving average of $9.73. Replimune Group has a 1-year low of $1.50 and a 1-year high of $16.33.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). Equities analysts anticipate that Replimune Group will post -2.82 earnings per share for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for the treatment of cancer. The company’s approach uses genetically engineered viruses designed to selectively replicate in tumors, directly destroy cancer cells and stimulate a broader immune response against malignant tissue.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 intended for use in patients with advanced solid tumors.